NGF   Click here for help

GtoPdb Ligand ID: 5026

Synonyms: beta-nerve growth factor | beta-NGF | Oxervate® | Sentinel®
Approved drug
NGF is an approved drug (EMA (2017), FDA (2018))
Compound class: Endogenous peptide in human, mouse or rat
Comment: Recombinant NGF (cenegermin, also known as cenegermin-bkbj) is used clinically as a peripherally selective agonist of TrkA and LNGFR. Note that the recombinant peptide is two amino acids shorter than the endogenous peptide, with the carboxy-terminal RA (Arg-Ala) removed.
Species: Human
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Jeon YH, Lee JY, Kim S. (2012)
Chemical modulators working at pharmacological interface of target proteins.
Bioorg Med Chem, 20 (6): 1893-901. [PMID:22227462]
2. MacDonald L, Torres R, Morra MR, Martin JH, Reinhardt JC. (2011)
High affinity human antibodies to human nerve growth factor.
Patent number: US7988967 B2. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 10/08/2007. Publication date: 02/08/2011.
3. Pons J, Rosenthal A. (2008)
Anti-NGF antibodies and methods using same.
Patent number: US7449616 B2. Assignee: Pfizer Inc.. Priority date: 24/12/2002. Publication date: 11/11/2008.
4. Wild KD Jr, Treanor JJS, Huang H, Inoue H, Zhang TJ, Martin F. (2009)
Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors.
Patent number: US7601818 B2. Assignee: Amgen, Inc., Medarex, Inc.. Priority date: 15/07/2003. Publication date: 13/10/2009.